Unichem Laboratories today said it has received approval from the US health regulator to market Divalproex Sodium Delayed Release tablets, indicated for seizure disorders, in the American market.
The company has got the US Food and Drug Administration for Divalproex Sodium Delayed Release tablets in strengths of 125 mg, 250mg and 500 mg, Unichem Laboratories said in a filing to the Bombay Stock Exchange (BSE).
The company already has nine drugs in the US that have been approved by the USFDA, it added.
Shares of Unichem Laboratories were trading at Rs 205.30 on BSE in late afternoon trade, up 5.26% from its previous close.
